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This article reviews trends in thoracic organ trans-
plantation based on OPTN/SRTR data from 1995 to
2004. The number of active waiting list patients for
heart transplants continues to decline, primarily be-
cause there are fewer patients with coronary artery
disease listed for transplantation. Waiting times for
heart transplantation have decreased, and waiting list
deaths also have declined, from 259 per 1000 patient-
years at risk in 1995 to 156 in 2004. Fewer heart trans-
plants were performed in 2004 than in 1995, but ad-
justed patient survival increased to 88% at 1 year and
73% at 5 years. Emphysema, idiopathic pulmonary fi-
brosis and cystic fibrosis were the most common indi-
cations among lung transplant recipients in 2004. Wait-
ing time for lung transplantation decreased between
1999 and 2004. Waiting list mortality decreased to 134
per 1000 patient-years at risk in 2004. One-year survival
following transplantation has improved significantly in
the past decade. The number of combined heart-lung
transplants performed in the United States remains
low, with only 39 performed in 2004. Overall unad-
justed survival, at 58% at 1 year and 40% at 5 years,
is lower among heart-lung recipients than among ei-
ther heart or lung recipients alone.
Note on sources: The articles in this report are based on the ref-
erence tables in the 2005 OPTN/SRTR Annual Report, which are
not included in this publication. Many relevant data appear in the
figures included here; other tables from the Annual Report that
serve as the basis for this article include the following: Tables 1.3,
1.6, 11.1a, 11.2b, 11.3. 11.4, 11.5, 11.6a, 11.6g, 11.6i, 11.7, 11.8,
11.11, 11.13, 11.14, 12.1a, 12.1b, 12.2, 12.3, 12.4a, 12.6a, 12.6e,
12.6g, 12.6i, 12.7a, 12.9a, 12.11, 12.12a, 12.13a, 13.1a, 13.2, 13.3,
13.4, 13.7, 13.11, 13.12, 13.14, and 13.15. All of these tables may
be found online at http://www.ustransplant.org.
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Introduction
This article reviews the OPTN/SRTR data on thoracic or-
gan transplantation in the United States in 2004 and the
previous decade. These robust data provide an opportunity
to describe the current state of heart, lung and heart-lung
transplantation with regard to waiting list characteristics
and transplant outcomes. Although there have been sub-
stantial advances in medical therapy since the mid 1990s,
thoracic organ transplantation remains an important treat-
ment option for selected patients with a failing heart, failing
lungs or both. Despite better donor organ selection and
utilization, the number of transplants performed has de-
clined in recent years and is still limited by the number of
donor organs available. Despite the decrease in the overall
transplant volume, outcomes for thoracic transplantation
have improved, as is evident in the increased short-term
patient survival rates. Among heart transplant recipients,
short-term (3-month and 1-year) patient survival has been
improving since 1995, while long-term (3-year and 5-year)
survival has remained steady. Both short- and long-term
patient survival rates have improved since 1995 for lung
transplant recipients.
In May 2005, a new deceased donor organ allocation sys-
tem for lung transplantation was introduced (1,2). The new
system determines priority for receiving a lung transplant
based primarily on severity of illness rather than time spent
on the waiting list. The long-term impact of this new sys-
tem is still to be determined; the development of the new
system is addressed in an accompanying article in this
report (3).
Unless otherwise noted, the statistics in this article are
drawn from the reference tables in the 2005 OPTN/SRTR
Annual Report. A companion article in this report, ‘An-
alytical Methods and Database Design: Implications for
Transplant Researchers, 2005,’ explains the methods of
data collection, organization and analysis that serve as the
basis for this article (4). Additional detail on the meth-
ods of analysis employed herein may be found in the
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reference tables themselves or in the Technical Notes of
the OPTN/SRTR Annual Report, both available online at
http://www.ustransplant.org.
Heart
Heart waiting list characteristics
The waiting list characteristics presented here represent
potential transplant recipients on the waiting list at the end
of each calendar year from 1995 to 2004. The total num-
ber of patients active on the heart waiting list continued
to decline during this time period, which is primarily a re-
flection of the decline in the percentage of transplant can-
didates with a coronary artery disease classification (Fig-
ure 1). There was a general reduction in the percentage
of patients aged 35–64 years, the peak age range for can-
didates with coronary artery disease (Figure 2). This may
reflect better outcomes resulting from improvements in
medical, interventional and surgical treatments for coro-
nary disease. The decline in the percentage of 35–64 year-
old patients began in 1997 and continued through 2004.
Other trends in characteristics of waiting list patients, such
as blood type and country of residence, did not change. The
number of female patients on the waiting list continued to
increase, from 20% in 1995 to 23% in 2004. There was also
an increase in the percentage of patients with a previous
organ transplant, from 3% in 1995 to 5% in 2004. Reflected
in these percentages is the increase in the percentage of
candidates with a previous heart or heart-lung transplant,
from 2.6% in 1995 to 4.3% in 2004.
Patients’ status at the end of each calendar year has
changed significantly since the creation of Status 1A and
Status 1B in 1999. The percentage of Status 2 patients de-
clined from 84% in 1997 to 72% in 2004. At the same time,
the percentage of Status 1B patients steadily increased,
from 14% in 1999 to 21% in 2004 (Figure 3). This change in-
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Source: 2005 OPTN/SRTR Annual Report, Table 11.1a.
Figure 1: Primary diagnoses of patients active on the heart
waiting list at year-end, 1995–2004.
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Source: 2005 OPTN/SRTR Annual Report, Table 11.1a.
Figure 2: Age distribution of patients active on the heart wait-
ing list at year-end, 1995–2004.
dicates that a relatively large percentage of patients shifted
from Status 2 to Status 1B.
The rules for listing as Status 1A include a high risk of
dying within 7 days of listing and having a ventricular assist
device (VAD) in place or other complications such as a VAD
infection or being on mechanical ventilatory support. As
of January 1, 2004, 37% of patients listed as Status 1A
remained listed as Status 1A at the end of 30 days. At 60
days, 18% of patients listed initially as Status 1A were still
listed as Status 1A.
Deaths on the heart waiting list
Both the number and the rate of deaths of patients on
the waiting list have declined significantly since 1995. An-
nual death rates per 1000 patient-years at risk declined
from 259 in 1995 to 156 in 2004 (Figure 4). This may re-
flect improved medical therapy and mechanical support for
patients with advanced heart failure (5–7). The improve-
ments in death rates occurred across age, ethnicity/race,
gender and blood type groups. From years 2000 to 2004,
the death rate among Status 1A patients declined from
Source: 2005 OPTN/SRTR Annual Report, Table 11.1a. 
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Figure 3: Waiting list status of patients active on the heart
waiting list at year-end, 1995–2004.
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Source: 2005 OPTN/SRTR Annual Report, Table 11.3.
Figure 4: Annual death rate of patients awaiting heart trans-
plantation, per 1000 patient-years at risk, 1995–2004.
1124 to 548 deaths per 1000 patient-years at risk, while
the death rates among Status 1B and Status 2 patients
declined less sharply (from 380 to 333 per 1000 patient-
years at risk among Status1B patients; and from 106 to 97
per 1000 patient-years at risk among Status 2 patients).
Heart transplant recipient characteristics
The number of transplant candidates undergoing heart
transplantation increased steadily in the 1990s, reach-
ing a peak in 1995, when 2363 heart transplant pro-
cedures were performed. Since then there has been
a steady decline in the number of heart transplant
procedures performed per year; 2016 transplants were per-
formed in 2004 (Figure 5). The number of heart transplants
per million population has also continued to decrease
over the past decade (from 8.99 procedures per million
population in 1995 to 6.87 procedures per million popula-
tion in 2004). The most notable decline occurred among
those ages 50–64 years; the incidence in this group
dropped from 35.86 transplants per million population in
1995 to 19.12 transplants per million population in 2004.
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Source: 2005 OPTN/SRTR Annual Report, Tables 11.4 and 11.5.
Figure 5: Number of heart transplants and incidence of trans-
plant per million population, 1995–2004.
One possible explanation for this gradual yet consistent
decline is the improvement in medical and surgical man-
agement of patients with end-stage heart disease (5–9).
Despite the decline in the total number of patients undergo-
ing heart transplantation, the percentage of recipients aged
65 years and above remained in the range of 8.5–10.3%
of all heart transplants in the years 2000–2004, which is
still higher than in 1995, when only 6% of recipients were
aged 65 years or older.
The waiting list status of heart transplant recipients at the
time of transplantation has changed little since the incep-
tion of the new classification system in 1999. The per-
centage of heart transplant recipients who were Status 1A
at the time of transplantation increased slightly between
2000 and 2004 (39.7% in 2000 to 40.6% in 2004). Dur-
ing the same interval, the percentage of recipients who
were Status 1B at the time of transplantation decreased
from 34.2% to 32.6%. The percentage of patients under-
going heart transplant at Status 2 has remained mostly un-
changed since 2000, increasing only from 26.0% in 2000
to 26.7% in 2004. With wider geographic sharing of donor
hearts for candidates who are Status 1A and 1B (if ap-
proved by the OPTN Board of Directors), the number of pa-
tients undergoing a heart transplant at Status 2 is expected
to decrease in favor of sicker candidates. More notable is
the decline in the percentage of transplant candidates on
life support (defined as inotrope infusion, intra-aortic bal-
loon pump or ventricular assist devices) at the time of trans-
plantation, from 68% in 2003 to 53% in 2004. The reason
for this 1-year decline is unknown. Heart transplant recipi-
ents’ primary diagnoses have changed slightly since 1995,
with an increase in the percentage of recipients diagnosed
with cardiomyopathy as the primary diagnosis (from 43%
in 1995 to 49% in 2004) and a decrease in the percent-
age of recipients diagnosed with coronary artery disease
(47% in 1995 to 38% in 2004). The term ‘cardiomyopa-
thy’ is broad and may include patients with ischemic car-
diomyopathy. Therefore, the change in numbers may be a
function of how the data were entered rather than a reflec-
tion of a change in disease prevalence. The percentage of
heart transplant recipients with a diagnosis of congenital
heart disease continues to increase (from 7% of recipients
in 1995 to 10% of recipients in 2004).
Immunosuppression therapy for heart transplantation
The immunosuppression regimen for heart transplanta-
tion has evolved over the past decade. Induction ther-
apy was used in 47% of heart transplant recipients in
2004, compared to 35% of recipients in 1995. With re-
gard to induction therapy agents, there has been a grad-
ual decline in use of ATG/NRATG/NRATS and muromonab-
CD3 (OKT3) and a gradual increase in use of rabbit an-
tithymocyte globulin (Thymoglobulin), daclizumab (Zena-
pax) and basiliximab (Simulect). Triple drug therapy re-
mains the cornerstone of immunosuppression therapy at 1
year after transplantation. Among recipients of heart trans-
plants in 2003, 86% were on corticosteroids 1 year later,
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compared to 90% of recipients of transplants in 1994.
Similarly, 88% of 2003 transplant recipients were on an-
timetabolites a year later, compared to 91% of recipients of
transplants in 1994. As expected, there has been a change
in the calcineurin inhibitor regimen: In 1994, 90% of heart
transplant recipients were receiving cyclosporine prepa-
rations and 3.5% were on tacrolimus. In 2003, 54% of
heart transplant recipients were on cyclosporine prepara-
tions and 53% were on tacrolimus. Similarly, azathioprine
use decreased significantly, from use by 88% of recipi-
ents in 1994 to use by 9% of recipients in 2003, while the
percentage of recipients using mycophenolate mofetil in-
creased from 2% to 78% during the same time period. An-
other notable trend in immunosuppression use in the past
decade is the declining number of recipients who needed
treatment for rejection episodes for 1 year following trans-
plantation (32% of recipients in 2003 compared to 40%
of recipients in 1994). The decline attests to the greater
potency of the new immunosuppression protocols. Con-
current data on the incidence of infection and malignancy
are not available.
Heart transplant outcomes
Deaths in the first year after heart transplantation have
steadily decreased, from 179 deaths per 1000 patient-
years at risk in 1995 to 131 deaths in 2003 (Figure 6).
Advances in medical and surgical management of heart
transplant recipients have translated into a declining death
rate in the first year following transplant that is irrespective
of ethnicity, sex, blood type, presence or absence of life
support, hospitalization status, primary diagnoses or the
waiting list status at the time of transplantation. The most
notable decline occurred in recipients less than 1 year old
and recipients 11–17 years old. Death rates for recipients
less than 1 year old decreased by about a third, and rates for
recipients 11–17 years old decreased by more than half. In
2003, the death rate for waiting list Status 1A recipients in
the first year after transplantation was still nearly twice the
death rate for waiting list Status 2 recipients (156 deaths
per 1000 patient-years at risk for Status 1A recipients vs.
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Source: 2005 OPTN/SRTR Annual Report, Tables 11.7.
Figure 6: Annual death rate of heart recipients in first year af-
ter transplantation, per 1000 patient-years at risk, 1995–2003.
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Figure 7: Unadjusted short- and long-term heart recipient
survival, by year of transplant, 1995–2003.
95 deaths for Status 2 recipients). Donor age appears to be
an important predictor of posttransplant survival. In 2003,
the recipient death rate in the first year after transplantation
was 135 deaths per 1000 patient-years at risk for donors
aged 50–64 years and 117 deaths per 1000 patient-years at
risk for donors aged 35–49 years. This information should
be interpreted within the context that no adjustment was
made for recipient variables.
In 2003 adjusted patient survival rates at 3 months, 1 year,
3 years and 5 years were 92%, 88%, 80% and 73%. The
adjusted 5-year survival rate was lowest among recipients
65 years old or older (68%). The 5-year adjusted patient
survival rate was 70% among female recipients and 74%
in male recipients. When examined at other time points—
such as 3 months, 1 year and 3 years—female recipients
continued to have inferior adjusted survival compared to
male recipients. At this point in time, it is unclear why
women would not fare as well. If this observation persists,
additional studies aimed at better understanding this find-
ing would be warranted. The 3-year and 5-year survival data
are based on cohorts of recipients of transplants in 2000–
2003 and 1998–2003, respectively. Adjusted graft survival
was nearly identical to adjusted patient survival with sim-
ilar trends in each recipient age group and both genders.
The unadjusted patient survival rate at 3 months, 1 year,
3 years and 5 years increased steadily between 1995 and
2003 (Figure 7). As expected, the prevalence of people liv-
ing with a functioning heart allograft increased from 11 644
in 1995 to 19 050 in 2004. This expanding population is a
testament to advances in the medical and surgical thera-
pies for end-stage heart disease and posttransplant care,
and may warrant a new discipline in cardiac care.
Lung
Lung waiting list characteristics
Lung transplantation currently remains a widely accepted
therapy for patients with a variety of end-stage lung
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Source: 2005 OPTN/SRTR Annual Report, Tables 1.3 and 12.1a.
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Figure 8: Active versus inactive lung waiting list patients at
year-end, 1995–2004.
diseases. A new deceased donor organ allocation system
was implemented in May 2005 (1,2). Whereas the previous
allocation system was based solely on time spent on the
waiting list, the new one is based on a priority score that
is determined by the severity of illness of patients on the
waiting list and by posttransplant survival. The long-term
impact of the new system on waiting list characteristics
has yet to be determined. The development of the new
system is reviewed in another article in this report (3).
The total number of patients on the lung transplant wait-
ing list was 3851 at the end of 2004, and has remained
relatively stable since 2001. However, since 1995 there
has been a slight increase in the ratio of inactive to active
waiting list patients (Figure 8). In 2004, there were 2167
active waiting list patients and 1684 inactive patients. The
increase in inactive patients probably has many causes,
including the early listing of patients with less severe dis-
ease in order to accrue time on the waiting list (10). As the
new donor allocation scheme is implemented, there may
be significant changes in the number and distribution of pa-
tients on the waiting list. Another potential reason for the
increase in the number of inactive patients on the waiting
list is that therapies for end-stage lung diseases have been
improved, particularly for primary pulmonary hypertension
(PPH) (11). Indeed, there were more patients with PPH on
the inactive waiting list than on the active waiting list in
2004 (18% vs. 8%, respectively).
The age distribution of patients on the active waiting list
for a lung transplant has changed slightly over the past
decade. In 2004, more than half of the patients on the
waiting list were more than 50 years old. The percentage
of waiting list patients between the ages of 18 and 34
years decreased slightly (Figure 9). The difference in the
age distribution may represent the increasing number of
active waiting list patients with idiopathic pulmonary fibro-
sis (IPF), which may have led to a decrease in the percent-
age of patients with cystic fibrosis (CF) and PPH. There
were no significant changes in the gender or ethnicity of
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Figure 9: Age distribution of active lung waiting list at year-
end, 1995–2004.
patients who were on the active waiting list in 2004 com-
pared to previous years. In 2004, active waiting list pa-
tients were most commonly female (55%), white (83%)
and blood type O (50%), and had not received a previous
transplant (97%). Approximately 45% of active waiting list
patients had already waited more than a year for a lung
transplant. While the distribution of time since listing has
been similar for patients on the list at the end of each year
since 1999, it is clearly different than in 1995, when only
28% of patients had waited more than a year (compared
to 45% in 2004). In 2004, the most common diagnoses
of active waiting list patients were chronic obstructive pul-
monary disease (COPD), or emphysema (32%), IPF (19%)
and CF (16%). The distribution of diagnoses in 2004 was
similar to the distribution in 2003, but since 1995 there has
been an overall increase in the percentage of patients with
IPF and a slight decrease in the percentage of patients with
CF, PPH and alpha-1 antitrypsin deficiency-related emphy-
sema (Figure 10).
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Figure 10: Primary diagnoses of patients active on the lung
waiting list, 1995–2004.
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Figure 11: Time to transplant for lung registrants, 25th per-
centile, 1995–2004.
The waiting time for new lung waiting list registrants de-
creased significantly among registrants ages 11 years and
older between 1999 and 2004. In addition, time to trans-
plant was shorter in all ethnic groups except Asians, and
in both males and females, in 2004 compared to 2003.
The 25th percentile of time to transplant is shown in
Figure 11.
Deaths on the lung waiting list
Death rates among waiting list patients have decreased
since 1995, but the rate in 2004 was similar to the rate in
2003 (Figure 12). The average death rate in 2004 was 134
deaths per 1000 patient-years at risk. In 2004, females con-
tinued to have a slightly lower death rate than males (123
compared to 149 per 1000 patient-years at risk), which is
consistent with the previous 9 years. It is not clear whether
the lower mortality rate among females is secondary to
lower severity of illness, the distribution of underlying di-
agnoses, or the possible influence of gender on lung dis-
ease. Asians had a markedly lower death rate (83 per 1000
patient-years at risk) than did other ethnic groups. How-
ever, this result should be interpreted with caution, be-
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Source: 2005 OPTN/SRTR Annual Report, Table 12.3.
Figure 12: Annual death rate of patients on the lung waiting
list, per 1000 patient-years at risk, 1995–2004.
cause the number of Asian patients on the transplant list
is relatively small (76 patients). Patients aged 65 years and
older and children between 1 and 5 years old had the high-
est death rates in 2004 (211 and 171 per 1000 patient-years
at risk, respectively).
Deceased donor lung transplant recipient
characteristics
There were 1157 deceased donor lung transplants per-
formed in 2004. This number has remained relatively sta-
ble since 2001, but represents an increase in the number
of transplants per year since 1995. The majority of trans-
plant recipients in 2004 were between the ages of 50 and
64 years. The percentage of recipients in this age group
was similar to the percentage in 2003, but had increased
significantly since 1995. There has been a respective de-
crease in the percentage of transplants performed among
patients between the ages of 35 and 49 years since 1995
(Figure 13). There have been no changes in the gender
(50% female), ethnicity (86% white) or blood group type
(45% type O) distribution of recipients of deceased donor
lung transplants since 1995.
In 2004, there were somewhat more bilateral lung trans-
plants performed compared to single lung transplants
(56% vs. 44%). This distribution differs from 1995, when
54% of the lung transplants were single lung transplants
and 46% were bilateral lung transplants. The change proba-
bly reflects a growing preference among transplant centers
for performing double lung transplants, because of the im-
proved long-term survival among bilateral lung transplant
recipients, particularly those with a diagnosis of emphy-
sema (8). Emphysema remains the most common diagno-
sis among lung transplant recipients; 37% of all transplants
were performed for this indication. IPF (24%) and CF (18%)
were the next most common diagnoses. While this distri-
bution is similar to the distribution in 2003, it has changed
since 1995 (Figure 14).
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Figure 13: Age distribution of deceased donor lung transplant
recipients, 1995–2004.
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Figure 14: Primary diagnosis of deceased donor lung trans-
plant recipients, 1995–2004.
Immunosuppression therapy after lung
transplantation
Immunosuppression after lung transplantation has
changed significantly since 1995. Induction therapy was
used in approximately 50% of all lung transplants per-
formed in 2004, whereas it was used in only 29% of lung
transplants in 1995. The induction therapies used most
commonly in 2004 were basiliximab (23%) and daclizumab
(15%). In 1995, antithymocyte globulin (ATG) induction
therapy was the therapy used most commonly (in 23% of
transplants). In 2004 baseline immunosuppression prior
to discharge included corticosteroids (97%), tacrolimus
(70%) and an antimetabolite, either azathioprine (44%) or
mycophenolate mofetil (47%). Calcineurin inhibitor use
has changed dramatically—from cyclosporine (77%) in
1995 to tacrolimus (70%) in 2004. For transplants in 2003,
maintenance immunosuppression administered between
discharge and 1 year posttransplant was essentially the
same as immunosuppression prior to discharge, except
that the use of sirolimus increased to 10% of lung trans-
plant cases. The immunosuppressive agent used most
commonly to treat acute rejection within the first year
after transplant was corticosteroids, which were used in
96% of acute rejection cases.
Deceased donor lung transplant outcomes
Among recipients of deceased donor lung transplants in
2003, the average death rate in the first year after trans-
plantation was 184 deaths per 1000 patient-years at risk,
a decrease since 2002, when the rate was 215 deaths per
1000 patient-years at risk, and a significant decrease since
1995, when the rate was 291 deaths per 1000 patient-years
at risk. Since 1995, the highest death rate has generally
been in the group of recipients aged 65 years and above,
who had a rate of 287 deaths per 1000 patient-years at
risk among 2003 recipients. Death rates in the group aged
35–49 years decreased significantly from previous years to
146 per 1000 patient-years at risk in 2003 recipients. First-
year death rates among most ethnic groups were similar,
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Source: 2005 OPTN/SRTR Annual Report, Table 12.7a.
Figure 15: Annual death rates during first year after deceased
donor lung transplant by primary diagnosis, 1995–2003.
except among Hispanics/Latinos, who appeared to have a
higher death rate (319 per 1000 patient-years at risk). The
reason for this difference is not clear; it may simply be a
reflection of the small number of Hispanics/Latinos who
received transplants in 2003 (47 transplant recipients). In
2004 there were no significant differences in death rates
by gender.
Lung transplant recipients who had received a previous
transplant had a higher death rate (402 per 1000 patient-
years at risk) than first-time recipients. In addition, recipi-
ents who were hospitalized, admitted to an intensive care
unit, or on life support had a higher annual death rate in
the first year after transplantation. Recipients with an un-
derlying diagnosis of PPH continued to have the highest
death rate in the first year after transplantation (285 per
1000 patient-years) compared to recipients with other diag-
noses. They were followed by recipients with IPF (225 per
1000 patient-years) (Figure 15). There was a slightly higher
death rate in the first year among recipients of double lung
transplants than among those with single lung transplants.
Recipients of lungs from donors who were 50–64 years
old had a higher death rate (221 deaths per 1000 patient-
years at risk) than did recipients of lungs from donors in
the other age groups. Note, however, that these subgroup
death rates have not been adjusted for other patient char-
acteristics.
After adjusting for age, race, gender and diagnosis, patient
survival rates for deceased donor lung transplant recipients
at 3 months, 1 year, 3 years and 5 years were 91%, 83%,
64% and 48%, respectively. Recipients over the age of
65 years had a slightly lower 5-year survival rate (41%)
than did younger recipients. An underlying diagnosis of
PPH portended a poor 3-month survival rate (76%), but 5-
year survival was comparable to rates for other diagnoses
(55%). Lung transplant recipients with an underlying diag-
nosis of IPF or alpha-1 antitrypsin deficiency had lower sur-
vival rates at 5 years—44% and 46%, respectively. African
Americans and multiracial/other patients tended to have
1194 American Journal of Transplantation 2006; 6 (Part 2): 1188–1197
Thoracic Transplantation, 1995–2004
40%
50%
60%
70%
80%
90%
100%
1995 1996 1997 1998 1999 2000 2001 2002 2003
Year
P
a
ti
e
n
t 
S
u
rv
iv
a
l 
(%
)
3-month survival 1-year survival 3-year survival* 5-year survival*
Source: 2005 OPTN/SRTR Annual Report, Table 12.13a.
*Values past 1999 for 5-year survival and 2001 for 3-year survival
not determined due to insufficient follow-up.
Figure 16: Unadjusted short- and long-term deceased donor
lung patient survival by year of transplant, 1995–2003.
worse 5-year survival rates (41% and 22%) than did whites,
Hispanics/Latinos and Asians. The latter three groups all
had 5-year survival rates of 50%. While the cause of this
difference is unknown, it may be related to racial dispari-
ties in human leukocyte antigen (HLA) matching. Adjusted
graft survival rates for the same time intervals and recip-
ient demographics are similar to adjusted patient survival
rates, because lung retransplantation is rarely performed.
The reason that so few patients receive second lung trans-
plants is that the outcomes are worse than outcomes of
first-time transplants. In an unadjusted graft survival model,
recipients who had received a previous lung transplant had
lower survival rates than first-time recipients at 3 months,
1 year, 3 years and 5 years (77%, 57%, 36% and 24%,
respectively). In addition, lung transplant recipients who
were hospitalized, in the intensive care unit, or on life sup-
port at the time of transplant had lower graft survival rates
at 5 years (45%, 35% and 44%, respectively). Yearly trans-
plant center volume has been reported previously to affect
survival (1). Between 2003 and 2004, it became clear that
centers with a volume greater than 21 transplants per year
had a higher 5-year patient survival rate (54%) than did
lower-volume centers (36–48%). However, there was no
significant difference in 5-year patient survival rates among
any of the other center volume categories. As was shown
in previous SRTR reports, donor ages of 50–64 years and
65 years and above were associated with relatively lower
5-year patient survival rates (43% and 35%, respectively).
Both short-term and long-term patient survival rates after
lung transplantation have, in general, continued to improve
since 1999 (Figure 16).
Heart-Lung
Heart-lung waiting list characteristics
For the sixth consecutive year the number of patients on
the active waiting list for a heart-lung transplant contin-
ued to decrease. From a high of 179 patients in 1998, the
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Figure 17: Number of heart-lung patients active on waiting
list at year-end and number of heart-lung transplants, 1995–
2004.
total number of active patients decreased to 83 in 2004
(Figure 17). Among these, 68% were female and 33%
were male, all were U.S. residents and none had received
a transplant previously. The reason for the decline in the
number of active waiting list patients is unclear, but difficul-
ties in obtaining a combined heart-lung block and the rela-
tively poor short- and long-term posttransplant survival out-
comes could be factors. Most waiting list patients (81%)
were adults older than 18 years. A total of 21% of the
patients were older than 50 years, which is often consid-
ered the upper age limit for heart-lung transplantation. The
most common diagnoses on the waiting list were congen-
ital heart disease (35%), PPH (18%) and CF (2%).
The median time to transplant has remained relatively sta-
ble with the 25th percentile of time to transplant at 284
days in 2004. This is up from 225 days in 2003 and down
from the decade high of 792 days in 1997. The increase
since 2003 in time to transplant has resulted in an increase
in the annual death rate, from 107 deaths per 1000 patient-
years at risk in 2003 to 159 deaths in 2004. There does not
appear to be any influence of age, sex, ethnicity or blood
type on death rates on the waiting list, but the low number
of waiting list registrants likely plays a role in this lack of
detectable differentiation. The death rate per 1000 patient-
years at risk among patients on the waiting list, by blood
group, was 151 for type O, 170 for type A and 207 for type
B. The rate could not be determined for type AB because
there were too few patients.
Heart-lung recipient characteristics
There were only 39 combined heart-lung transplants per-
formed in 2004, a decline from a high of 69 in 1995 and an
increase from a low of 27 in 2001. Only 15% of the recipi-
ents were less than 18 years old, and 67% were between
the ages of 18 and 49 years. Thirty percent of the recipi-
ents were hospitalized, and 26% were on life support at the
time of transplant. Males and females were nearly equally
represented, with males accounting for 49% of the recipi-
ents and females accounting for 51%. The most common
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diagnoses were congenital heart disease (28% of diag-
noses) and PPH (31% of diagnoses). This pattern has not
changed over the past decade.
Blood type does not appear to have had a significant im-
pact on any aspect of heart-lung transplantation. Candi-
dates with blood type O represented 54% of the waiting
list, while 31% of candidates had type A, 11% had type
B and 4% had type AB. Similarly, among recipients, 49%
had blood type O, 23% had type A, 23% had type B and
5% had type AB.
Heart-lung recipient outcomes
The SRTR database includes 55 transplant centers that
performed heart-lung transplants between 1995 and 2004.
Thirty-four of these centers (63%) did not perform a com-
bined transplant in 2004. Most centers that did perform
heart-lung transplants performed only one transplant. The
greatest number of combined transplants performed at
one center was five, and two centers performed four trans-
plants.
Reported unadjusted patient survival rates at 3 months,
1 year, 3 years and 5 years were 70%, 58%, 52% and 40%.
The age-adjusted survival rates appeared to be better (at all
time points) for recipients with PPH than for recipients with
congenital heart disease. Survival rates for PPH were 79%,
79%, 71% and 57% for the 3-month, 1-year, 3-year and 5-
year periods. For recipients with congenital heart disease,
survival rates were 67%, 45%, 49% and 40% (Figure 18).
These results have not improved over the past decade.
The first-year posttransplant annual death rate, reported
per 1000 patient-years at risk, was up to 857 for recipi-
ents with transplants in 2003, the last year with adequate
follow-up. Fourteen of the 28 recipients of transplants that
year died. Because the number of candidates on the active
waiting list and the number of recipients are too small to
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Figure 18: Adjusted heart-lung patient survival at 3 months,
1 year, 3 years and 5 years, by diagnosis.
permit multivariate analysis, the significance of these num-
bers is unknown. However, there is no evidence that the
death rate in the first year after heart-lung transplantation
was significantly related to place of residence, blood type,
age or indication for transplant. First-year mortality rates
seem to be higher among recipients in the intensive care
unit and on life support at the time of transplant.
The prevalence of people living with a functioning heart-
lung transplant has changed little over the past decade,
remaining in the 230–250 range. The steady prevalence
reflects the fact that the number of transplant recipient
deaths and the number of new recipients remain about the
same from year to year. It also means that survival rates
have not improved over the last decade, despite improve-
ments in immunosuppression and general medical care.
Conclusion
Thoracic transplantation remains an important and viable
treatment strategy for patients with end-stage heart and
lung disease. The past few years have seen a decline in the
total number of heart transplants performed and decreas-
ing waiting list mortality. This is likely due to improvements
in medical and surgical therapies for heart disease overall.
The introduction of ventricular assist devices has changed
the profile of patients waiting for and ultimately receiving
heart transplants. In recent years, short- and long-term sur-
vival rates for lung transplant recipients have improved,
with a more marked increase in short-term survival. Com-
pared to previous years and despite the persistent prob-
lem of donor organ availability, more double lung trans-
plants than single lung transplants are being performed.
Although waiting list characteristics had not changed sub-
stantially through 2004, recent changes in the organ alloca-
tion system for lung transplantation will likely change the
profile of patients on the waiting list and those receiving
transplants in the future. More time is needed to assess
the overall impact of this new system. A limited number of
heart-lung transplant operations are performed each year in
the United States, probably due in part to the limited avail-
ability of heart-lung organ blocks. The survival outcomes of
combined heart-lung transplants remain lower than those
of heart or lung transplants alone.
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